Stockholders' Equity

3 Months Ended

Mar. 31, 2020

STOCKHOLDERS’ EQUITY

Sale of Common Stock Under ATM Agreement

On April 5, 2019, we entered into a new collective at-market-issuance (ATM) sales agreement with Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC and B. Riley FBR, Inc. (the “April 2019 ATM Agreement”). The sales agreement prospectus filed with our shelf registration statement on Form S-3, filed with the SEC on March 20, 2020, registers an aggregate offering price of $75 million under the April 2019 ATM Agreement.

Through March 31, 2020, we raised aggregate net proceeds of $1.8 million under the April 2019 ATM Agreement, pursuant to an automatic shelf registration statement on Form S-3, filed with the SEC on April 5, 2019. These proceeds and any future proceeds raised will support the advancement of our in-development drug candidates, activities in connection with the launch of these drugs (including the hiring of personnel, building inventory supply and equipment purchases), completing acquisitions of assets, businesses, or securities, and for all other working capital purposes.


Description of Financing Transaction	No. of Common Shares Issued	Proceeds Received (Net of Broker Commissions and Fees )
Common shares issued pursuant to the April 2019 ATM Agreement during the year ended December 31, 2019	221,529	$	1,814

There were no sales of our common shares under the April 2019 ATM Agreement during the three months ended March 31, 2020.